We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

29 hedge funds and large institutions have $1.21M invested in Cardiff Oncology in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

29% more capital invested

Capital invested by funds: $936K → $1.21M (+$272K)

5.22% more ownership

Funds ownership: 0.07% → 5.29% (+5.2%)

22% less funds holding

Funds holding: 37 → 29 (-8)

50% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 14

Holders
29
Holders Change
-8
Holders Change %
-21.62%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
2
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SM
Sabby Management
Florida
+$2.09M
2
CH
CVI Holdings
Delaware
+$857K
3
Renaissance Technologies
Renaissance Technologies
New York
+$538K
4
EP
Elkhorn Partners
Nebraska
+$181K
5
SNB
Security National Bank
Nebraska
+$115K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$119K
2
PFS
Prospera Financial Services
Texas
-$44K
3
VF
Virtu Financial
New York
-$37K
4
California Public Employees Retirement System
California Public Employees Retirement System
California
-$27K
5
Northern Trust
Northern Trust
Illinois
-$20K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$578K +$2.09M +125,092 New
CH
2
CVI Holdings
Delaware
$237K +$857K +51,241 New
Renaissance Technologies
3
Renaissance Technologies
New York
$157K +$538K +32,180 +1,801%
EP
4
Elkhorn Partners
Nebraska
$69K +$181K +10,833 +269%
SNB
5
Security National Bank
Nebraska
$32K +$115K +6,867 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$30K -$119K -7,138 -52%
BlackRock
7
BlackRock
New York
$26K +$150 +9 +0.2%
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$19K +$59.5K +3,560 +572%
Citadel Advisors
9
Citadel Advisors
Florida
$18K +$65.5K +3,919 New
TSS
10
Two Sigma Securities
New York
$12K +$44.6K +2,667 New
UBS Group
11
UBS Group
Switzerland
$11K +$35.1K +2,100 +686%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$8K – – –
CAPTRUST Financial Advisors
13
CAPTRUST Financial Advisors
North Carolina
$4K – – –
Barclays
14
Barclays
United Kingdom
$2K – – –
MAM
15
Meeder Asset Management
Ohio
$1.74K +$5.03K +301 +401%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$1K – – –
PCM
17
Princeton Capital Management
New Jersey
$1K +$17 +1 +0.4%
Fifth Third Bancorp
18
Fifth Third Bancorp
Ohio
$1K +$2.32K +139 New
PFS
19
Prospera Financial Services
Texas
– -$44K -1,769 Closed
VF
20
Virtu Financial
New York
– -$37K -1,471 Closed
California Public Employees Retirement System
21
California Public Employees Retirement System
California
– -$27K -1,072 Closed
Northern Trust
22
Northern Trust
Illinois
– -$20K -779 Closed
Bank of New York Mellon
23
Bank of New York Mellon
New York
– -$11K -444 Closed
RJA
24
Raymond James & Associates
Florida
– -$8K -306 Closed
IAA
25
Independent Advisor Alliance
North Carolina
– -$6K -241 Closed
1
2

CRDF Hedge Fund Activity: Q2 2018 in Review

29 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2018, worth a combined $1.21M — up 29% from $936K a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CRDF and 7 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 9 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.09M. The largest seller was Vanguard Group, cutting an estimated $119K.

  • 29 institutional investors held Cardiff Oncology (CRDF) as of Q2 2018, down from 37 in Q1 2018.
  • Funds reported $1.21M of Cardiff Oncology stock for Q2 2018, up 29% quarter-over-quarter.
  • 7 funds opened new Cardiff Oncology positions in Q2 2018 and 14 closed out, a net change of -7 holders.
  • The largest Cardiff Oncology buyer in Q2 2018 was Sabby Management, an estimated $2.09M added.
  • The largest Cardiff Oncology seller in Q2 2018 was Vanguard Group, an estimated $119K sold.

Based on aggregated 13F filings for Q2 2018.